{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:07:26Z","timestamp":1765004846806},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.ejphar.2009.10.025","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T08:15:40Z","timestamp":1255767340000},"page":"S17-S25","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S1","title":["Infliximab therapy for patients with inflammatory bowel disease: 10years on"],"prefix":"10.1016","volume":"623","author":[{"given":"Gert","family":"Van Assche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rutgeerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2009.10.025_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00054725-200403000-00002","article-title":"Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis","volume":"10","author":"Arts","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2009.10.025_bib3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2009.10.025_bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","article-title":"Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease","volume":"8","author":"Baldassano","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"12","author":"Baumgart","year":"2007","journal-title":"Rev. Lancet"},{"key":"10.1016\/j.ejphar.2009.10.025_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of Crohn's disease","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/gut.2005.075937","article-title":"Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study","volume":"55","author":"Biancone","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib8","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2009.10.025_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.dld.2003.12.014","article-title":"Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease","volume":"36","author":"Borrelli","year":"2004","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejphar.2009.10.025_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.025_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00042737-200501000-00016","article-title":"Ciclosporin use in acute ulcerative colitis: a long-term experience","volume":"17","author":"Campbell","year":"2005","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00005176-200305000-00007","article-title":"A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn's disease","volume":"36","author":"Cezard","year":"2003","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.ejphar.2009.10.025_bib15","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ibd.3780070507","article-title":"Infliximab for patients with refractory ulcerative colitis","volume":"7","author":"Chey","year":"2001","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2009.10.025_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","article-title":"Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy","volume":"99","author":"Colombel","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2036.2001.00956.x","article-title":"Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease","volume":"15","author":"Cornillie","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2009.10.025_bib21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohn's disease","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2009.10.025_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0016-5107(99)80017-0","article-title":"Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine","volume":"50","author":"D'Haens","year":"1999","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.ejphar.2009.10.025_bib23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.025_bib24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.ejphar.2009.10.025_bib25","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis. Res. Ther."},{"key":"10.1016\/j.ejphar.2009.10.025_bib26","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/art.20164","article-title":"Anti-tumor necrosis factor alpha therapy and heart failure","volume":"50","author":"Dinesh","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.ejphar.2009.10.025_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib30","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.20863","article-title":"Corticosteroids but not Infliximab Increase Short-term Infectious Complications in patients with Ulcerative Colitis","author":"Ferrante","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2009.10.025_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort","volume":"133","author":"Fr\u00f8slie","year":"2007","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ejphar.2009.10.025_bib33","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/j.gastro.2005.06.022","article-title":"Increased risk for demyelinating diseases in patients with inflammatory bowel disease","volume":"129","author":"Gupta","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib35","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2009.10.025_bib36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"A. randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib39","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib40","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(09)60396-6","article-title":"Successive treatment with cyclosporine and infliximab in severe ulcerative colitis (UC)","volume":"136","author":"Leblanc","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib43","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","article-title":"A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine","volume":"128","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib44","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/gast.2001.28703","article-title":"Inflammatory bowel disease is not associated with an increased risk of lymphoma","volume":"121","author":"Lewis","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib45","article-title":"Safety of infliximab and other Crohn's disease therapies \u2014 updated Treat registry data with over 10,000 patient-years of follow-up","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib46","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn's disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib47","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib49","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/00365520801957149","article-title":"Predictors of severe Crohn's disease","volume":"43","author":"Loly","year":"2008","journal-title":"Scand J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(09)60659-4","article-title":"Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study","volume":"136","author":"Louis","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J. Ped. Gastroenterology & Nutrition"},{"key":"10.1016\/j.ejphar.2009.10.025_bib52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","article-title":"Intentional infliximab use during pregnancy for induction or maintenance of remission of Crohn's Disease","volume":"21","author":"Mahadevan","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2009.10.025_bib53","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2036.2004.01904.x","article-title":"The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study","volume":"19","author":"Marchal","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2009.10.025_bib54","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.cgh.2006.05.011","article-title":"Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease","volume":"4","author":"Markowitz","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib100","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of the severity of Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)","volume":"30","author":"Mary","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib55","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib56","article-title":"Cyclosporine (CsA) and infliximab (Infl) as acute salvage therapies for each other in severe steroid refractory ulcerative colitis (UC)","volume":"132","author":"Maser","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib57","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","article-title":"Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone","volume":"98","author":"Modigliani","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib58","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cgh.2006.04.001","article-title":"Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis","volume":"4","author":"Moskovitz","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib59","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/gut.31.3.325","article-title":"Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation","volume":"31","author":"Olaison","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib61","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin. Gastroenter. Hepatol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib62","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn's disease with S-mercaptopurine. A long-term randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib63","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib64","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00004836-200607000-00004","article-title":"Infliximab for hospitalized patients with severe ulcerative colitis","volume":"40","author":"Regueiro","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib65","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","article-title":"Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?","volume":"13","author":"Rosh","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2009.10.025_bib103","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of Retreatment with Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib66","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib67","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.ejphar.2009.10.025_bib69","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","article-title":"AGA technical review on perianal Crohn's disease","volume":"125","author":"Sandborn","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib70","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib71","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"6","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib72","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn's disease previously treated with infliximab","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib73","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.14309\/00000434-200809001-01117","article-title":"SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy","volume":"103","author":"Sandborn","year":"2008","journal-title":"Am. J. Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib74","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib75","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.20927","article-title":"Mucosal healing predicts long-term outcome, of maintenance therapy with infliximab in Crohn's disease","author":"Schnitzler","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2009.10.025_bib77","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib78","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib79","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib80","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib81","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jamcollsurg.2006.12.044","article-title":"Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis","volume":"204","author":"Selvasekar","year":"2007","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.ejphar.2009.10.025_bib82","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1345\/aph.10395","article-title":"Use of infliximab in pediatric patients with inflammatory bowel disease","volume":"35","author":"Serrano","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2009.10.025_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(08)60670-8","article-title":"Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis","author":"Siegel","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib84","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","article-title":"Clinical course during the first 10years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)","volume":"44","author":"Solberg","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib85","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis and Rheumatism."},{"key":"10.1016\/j.ejphar.2009.10.025_bib102","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor a for Crohn's Disese","volume":"337","author":"Targan","year":"1997","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2009.10.025_bib86","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib87","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1136\/gut.2005.081950b","article-title":"European evidence based consensus on the diagnosis and management of Crohn's disease: current management","volume":"1","author":"Travis","year":"2006","journal-title":"Gut 55 Suppl."},{"key":"10.1016\/j.ejphar.2009.10.025_bib88","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","article-title":"Randomized, double-blind comparison of 4mg\/kg versus 2mg\/kg intravenous cyclosporine in severe ulcerative colitis","volume":"125","author":"Van Assche","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib89","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9270(02)05909-9","article-title":"Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease","volume":"98","author":"Van Assche","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib90","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib91","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy","volume":"46","author":"Van Den Bosch","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.ejphar.2009.10.025_bib92","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized placebo-controlled trial (ASSERT)","volume":"52","author":"Van der Heijde","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2009.10.025_bib93","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2006.07.018","article-title":"Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn","volume":"4","author":"Vasiliauskas","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib94","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2009.10.025_bib95","first-page":"32","article-title":"Autoimmunity associated with anti tumor necrosis factor alpha therapy in Crohn's disease","volume":"125","author":"Vermeire","year":"2003","journal-title":"A prospective cohort study. Gastroenterology"},{"key":"10.1016\/j.ejphar.2009.10.025_bib96","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2009.10.025_bib98","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ibd.20069","article-title":"Linear growth improves during infliximab therapy in children with chronically active severe Crohn\u00b4s disease","volume":"13","author":"Walters","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2009.10.025_bib99","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.2005.041129","article-title":"Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann. Rheum. Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909009169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909009169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T03:18:48Z","timestamp":1590203928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299909009169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":99,"alternative-id":["S0014299909009169"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2009.10.025","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}